The news: Young, healthy people will be deliberately infected with covid-19 in the first ever “human challenge trial”, set to begin at a London hospital in January. The study, announced today, will recruit up to 50 healthy volunteers aged between 18 and 30. The UK government has pledged to invest GBP33.6 million ($44 million) into the trial, which will be carried out in partnership with hVIVO, a company with experience in viral human challenge trials. It will take place at the Royal Free London NHS Foundation Trust, if it gets ethical and regulatory approval. Volunteers will be paid, isolated for the duration of the study, and monitored for up to a year afterwards to check for any side effects.
Why do this? The hope is that this trial will make it easier to closely study the disease, with the aim of speeding up the development of a vaccine. In the first phase of the trial, researchers would try to work out the smallest level of exposure required for someone to catch covid-19. Next, they could test if a vaccine prevents infection. They could also explore other potential treatments, and study the immune response. The benefit of this approach is that it lets researchers study vaccine candidates side-by-side to see which is the most effective. “Deliberately infecting volunteers with a known human pathogen is never undertaken lightly,” said professor Peter Openshaw, co-investigator on the study at Imperial College London, in a statement. “However, such studies are enormously informative about a disease, even one so well studied as covid-19. It is really vital that we move as fast as possible towards getting effective vaccines and other treatments for covid-19, and challenge studies have the potential to accelerate and de-risk the development of novel drugs and vaccines.”
Controversial: There are obvious risks to this approach. The volunteers could become seriously ill, and even die. There are huge trials underway to test treatments and vaccines in people who are already being infected with covid-19 naturally. And given the challenge study doesn’t start until January, we may already be close to having an effective vaccine by then.
